The main market opportunities for breast cancer antibody drug conjugates (ADCs) lie in addressing unmet needs in HER2-positive and HER2-low tumors, leveraging precision targeting and reducing systemic ...
Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...
Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...
Global Cancer Antibody Drug Conjugates Market Opportunity USD 70 Billion Opportunty By 2031 ...
Drugs commonly used in cancer immunotherapy carry the risk for ocular adverse events, according to a speaker.In a ...
Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against ...
The Antibody-Drug Conjugates (ADC) Market Size was valued at around US $11.9 billion in 2024, the market is projected to surge past ...
MedPage Today on MSN
Paradigm Shift in Metastatic TNBC to Trop2-Targeted Antibody-Drug Conjugates
BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...
GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...
New research has uncovered a built-in resistance mechanism to antibody–drug conjugates in some breast cancers and identified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback